Clinical Trial

Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Study acronym: TALIM
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy of Teclistamab (Te) and autologous lymphocyte infusions (ALI) in relapse refractory multiple myeloma. The main question it aims to answer is: which is the Duration of response (DoR) with Teclistmab and ALI? Participants will receive Te for 5 cycles. Participants in PR or better after the first five cycles of Te monotherapy will continue treatment with Te in combination with ALI administration starting from cycle 6
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-14.
Trial Details
NCT Number NCT06880601
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
Enrollment 52 participants
Start Date 2025-11-01
Primary Completion 2029-11-01 (estimated)
Study Completion 2029-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-03